

CSE Symbol: IME  
OTC PINK Symbol: IMEXF  
Frankfurt/Stuttgart Stock Exchanges: DPD2

NR-2016-IME-18

## **Dr. Edward Messing, Chief of Urology, U Rochester Medical Center Joins Imagin Medical's Scientific Board of Advisors**

*Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in detecting bladder cancer through endoscopes.*

---

**Vancouver, B.C. and Boston, MA**, September 22 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the “Company”) announced today that Dr. Edward Messing, Chair of Urology, University of Rochester Medical Center has joined Imagin’s Scientific Board of Advisors.



Dr. Messing is a renowned expert in the diagnosis and treatment of cancers of the bladder, prostate, kidney, and other genitourinary organs. He has conducted extensive research in the basic biology of bladder and prostate cancers and has been the principal investigator on numerous clinical studies for the detection, prevention and treatment of genitourinary cancers. Dr.

Messing received his M.D. degree from New York University, performed his surgery training at NYU-Bellevue Hospital and his Urology Residency at Stanford University. He was Director of the Urologic Oncology Program at the University of Wisconsin and assumed his current position at the University of Rochester School of Medicine and Dentistry in August, 1995.

Dr. Messing has been involved in multiple clinical studies relevant to Imagin’s focus. Having both Dr. Messing and Dr. Stavros Demos, the inventor of the i/Blue, at the same institution, is a major advantage that will help drive Imagin’s development and clinical trial programs.

“We are excited to have Dr. Messing join our Scientific Advisory Board. He brings a wealth of knowledge about bladder cancer and its treatment and will provide invaluable insight for us as we move forward,” said Jim Hutchens, Imagin President and CEO.

### **About Imagin Medical**

*Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50%*

*recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at [www.imaqinmedical.com](http://www.imaqinmedical.com).*

**ON BEHALF OF THE BOARD:**

*Jim Hutchens,*

President & CEO

**For further information, contact:**

Bill Galine, Investor Relations

Telephone: (775) 737-3292

Email: [billgaline@gmail.com](mailto:billgaline@gmail.com)

Information set forth in this news release contains forward-looking statements. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.